DUBLIN, Calif. — Tria Beauty, which creates at-home light-based skin care products, has announced the completion of $27 million in equity and $10 million in debt financing to help support the continued growth of the company and global commercialization of its light-based skin care products.
"This new financing allows Tria to continue its exceptional growth by introducing our existing products to consumers worldwide, while continuing to invest in the development and clinical validation of new light-based treatments that address consumers' most important skin care concerns," stated Kevin Appelbaum, Tria Beauty CEO.
"We remain focused on fulfilling our promise to consumers that Tria will continue to bring innovative skin care treatments out of the doctor's office and into the home, delivering a level of performance never before available over the counter and at an affordable cost," Appelbaum added.
Tria Beauty also announced the addition of two new members to its board of directors: Mike Valentino and Ed Unkart.
Valentino joins after serving as president and CEO of Xanodyne Pharmaceuticals and previously of Adams Respiratory Therapeutics. Adams completed its initial public offering in July 2005 and in December 2007 entered into a definitive agreement to be acquired by Reckitt Benckiser for approximately $2.3 billion.
Ed Unkart joins the Tria board of directors following tenures as CFO at such medical device companies as SurgRx (acquired by Ethicon Endo-Surgery), Novacept (acquired by Cytyc) and FemRx (acquired by Johnson & Johnson). Unkart also will serve as chairman of the audit committee for Tria Beauty.
Tria Beauty has developed the Tria laser hair removal system, an FDA-cleared hair removal laser available for at-home use. In 2010, Tria introduced its skin clarifying system, combining an FDA-cleared blue light treatment for mild to moderate inflammatory acne with a cleanser and serum for overall complexion improvement.